A 77-year-old male patient with herpes zoster pain in left lower limb developed toxic epidermal necrolysis after treated with paracetamol and codeine tablets (I), 1 tablet per day, for 20 days and ibuprofen sus-tained-release capsules 0.3 g. After medication, dark purple erythema and blisters appeared on the trunk and limbs, accompanied by pain. After 3 days, the area of erythema became larger, the number of blisters increased, and part of them fused into bullae. Nielsen's sign was positive, and tenderness was positive; the oral mucosa was diffusely flushed without erosion, the skin lesions gradually aggravated and spread all over the body. He was diagnosed with bullous epidermal necrolysis type drug eruption and hospitalized. He had lip and oral mucosa erosion on the second day after hospitalization. After discontinuing the suspected drugs of paracetamol and codeine tablets (I) and ibuprofen, the patient was given antihistamine and anti-allergic treatment: methylprednisolone sodium succinate for injection 60 mg·d-1 intravenously, desloratadine tablets 8.8 mg·d-1 orally, cetirizine hydrochloride tablets 10 mg·d-1 orally, fluticasone propionate cream appropriate for external use, compound phellodendron amurense solution appropriate for external use to prevent infection, calcium carbonate to prevent osteoporosis, omeprazole enteric-coated capsules to inhibit acid and protect stomach, and other treatments. On the 6th day, most of the patients' lip scabs fell off, the ero-sion surface of oral mucosa was basically healed, the blisters on the trunk and limbs were dry and scabbed, and there was no new rash. The drug eruption was significantly improved. On the 7th day, the patients recovered and dis-charged from the hospital. It is considered that the occurrence of bullous epidermal necrolysis drug eruption is related to the drug allergy caused by the use of paracetamol and codeine tablets (I) and ibuprofen.
1.Liotti L, Caimmi S, Bottau P, et al. Clinical features, outcomes and treatment in children with drug in-duced Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Acta Biomed, 2019, 90(3-S): 52-60. DOI: 10.23750/abm.v90i3-S.8165.
2.Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. F1000Res, 2020, 9. DOI: 10.12688/f1000research.24748.1.
3.胡润凯,韩伟超,谢保城,等.别嘌醇致HLA-B~*5801阴性患者中毒性表皮坏死松解症1例[J].药物流行病学杂志, 2022, 31(6): 430-432. [Hu RK, Han WC, Xie BC, et al. A case of toxic epidermal necrolysis in HLA-B~*5801 negative patients caused by allopurinol[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(6): 430-432.] DOI: 10.19960/j.cnki.issn1005-0698.2022.06.014.
4.国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[S]. 2012.
5.刘敏, 李忠东. 实例探讨药物引起SJS或TEN的评分方法——Naranjo评分与ALD评分比较[J]. 中国药物应用与监测, 2014, 11(4): 247-249. [Liu M, Li ZD. Assessment tools for drug-induced SJS or TEN by a case study - Naranjo score versus ALDEN score[J]. Chinese Journal of Drug Application and Monitoring, 2014, 11(4): 247-249.] DOI: CNKI:SUN:YWYY.0.2014-04-021.
6.安继红,吕维玲,张永州,等.我院2016~2017年药疹发生率、皮疹特点分析[J].黑龙江医药科学, 2019, 42(1): 103-104, 106. [An JH, Lu WL, Zhang YZ, et al. Analysis on the incidence and characteristics of drug eruption in our hospital from 2016 to 2017[J]. Helongjiang Medicine AND Pharmacy, 2019, 42(1): 103-104, 106.] DOI: 10.3969/j.issn.1008-0104.2019.01.045.
7.Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diag-nosis, differential diagnosis, prevention, and treatment[J]. J Am Acad Dermatol, 2013, 69(2): 187.e1-16; quiz 203-204. DOI: 10.1016/j.jaad.2013.05.002.
8.杜玉娟,赵甡慧,杨宏昕.布洛芬致儿童中毒性表皮坏死松解症1例[J].药物流行病学杂志, 2021, 30(8): 569-571. [Du YJ, Zhao SH, Yang HX. A case of toxic epidermal necrolysis in children caused by ibuprofen[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(8): 569-571.] DOI: 10.19960/j.cnki.issn1005-0698. 2021.08.015.
9.国家药品监督管理局.国家药监局关于修订对乙酰氨基酚常释及缓释制剂说明书的公告(2020年 第15号)[EB/OL]. (2020-03-03) [2022-08-19]. https://www.nmpa.gov.cn/xxgk/ggtg/ypshmshxdgg/20200303171601354.html.
10.Jennifer D, Salisbury RE. Morbidity and mortality of mucocutaneous diseases in the pediatric popula-tion at a tertiary care center[J]. J Burn Care Res, 2007, 8: 865-870. DOI: 10.1097/BCR.0b013e318159a3c7.
11.余炳前, 王文菊, 骆志成. 重症药疹112例分析[J].中国皮肤性病学杂志, 2017, 31(6): 623-626. [Yu BQ, Wang WJ, Luo ZC. Analysis of 112 cases of severe drug eruption[J]. The Chinese Journal of Dermatovenereology, 2017, 31(6): 623-626.] DOI: 10.13735/j.cjdv.1001- 7089.201610096.
12.陈昆,陈虹,方洁. 1例中毒性表皮坏死松解症继发脓毒血症的药物治疗及监护[J]. 上海医药, 2022, 43(9): 58-62. [Chen K, Chen H, Fang J. Pharmaceutical care of a case of toxic epidermal necrolysis secondary to sep-sis[J].Shanghai Pharmaceutical, 2022, 43(9): 58-62.] DOI: 10.3969/j.issn.1006-1533.2022.09.017.
13.谷彤彤, 张航, 程楚豪, 等. 布洛芬与对乙酰氨基酚的药品不良反应对比分析[J]. 中国医院用药评价与分析, 2022, 22(9): 1145-1148, 1152. [Gu TT, Zhang H, Cheng CH, et al. Comparative analysis on adverse drug reac-tions between ibuprofen and acetaminophen[J].Evaluation and Analysis of Drug-use in Hospitals of China, 2022, 22(9): 1145-1148, 1152.] DOI: 10.14009/j.issn.1672-2124.2022.09.027.